Merck
1Q Revenues: $15.8 billion (+9%)
1Q Earnings: $4.8 billion (+69%)
Comments: Keytruda sales were $6.9 billion in the quarter, up 20% driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer and renal cell carcinoma, as well as non-small cell lung cancer (NSCLC) in the U.S. Gardasil sales were up 14% to $2.2 billion. Januvia sales were down 24% to $670 million, primarily due to lower pricing and demand in the U.S., as well as ongoing generic competition. PROQUAD, M-M-R II and VARIVAX sales were up 8% to $570 million. Bridion sales were down 10% to $440 million, primarily due to generic competition in certain ex-U.S. markets. Lagevrio sales were down 11% to $350 million. Lynparza sales were up 6% to $292 million. VAXNEUVANCE sales were up 106% to $219 million driven by continued uptake for pediatric indication in the U.S. and launches in Europe. Rotateq sales were down 27% to $216 million, primarily due to timing of shipments in China and public-sector buying patterns in the U.S.